WO2006036406A3 - Live microbial microbicides - Google Patents
Live microbial microbicides Download PDFInfo
- Publication number
- WO2006036406A3 WO2006036406A3 PCT/US2005/030216 US2005030216W WO2006036406A3 WO 2006036406 A3 WO2006036406 A3 WO 2006036406A3 US 2005030216 W US2005030216 W US 2005030216W WO 2006036406 A3 WO2006036406 A3 WO 2006036406A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antimicrobial polypeptide
- microbicides
- bacteria
- live microbial
- commensal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/36—Neisseria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/38—Pseudomonas
- C12R2001/385—Pseudomonas aeruginosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05814101A EP1786445B1 (en) | 2004-08-25 | 2005-08-25 | Live microbial microbicides |
AT05814101T ATE511848T1 (en) | 2004-08-25 | 2005-08-25 | LIVE MICROBIAL MICROBICIDES |
US11/710,512 US8349586B1 (en) | 2004-08-25 | 2007-02-26 | Commensal strain of E. coli encoding an HIV GP41 protein |
US13/735,638 US20130209407A1 (en) | 2004-08-25 | 2013-01-07 | Live microbial microbicides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60405104P | 2004-08-25 | 2004-08-25 | |
US60/604,051 | 2004-08-25 | ||
US68837605P | 2005-06-08 | 2005-06-08 | |
US60/688,376 | 2005-06-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/710,512 Continuation-In-Part US8349586B1 (en) | 2004-08-25 | 2007-02-26 | Commensal strain of E. coli encoding an HIV GP41 protein |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006036406A2 WO2006036406A2 (en) | 2006-04-06 |
WO2006036406A3 true WO2006036406A3 (en) | 2006-05-18 |
Family
ID=35949951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/030216 WO2006036406A2 (en) | 2004-08-25 | 2005-08-25 | Live microbial microbicides |
Country Status (4)
Country | Link |
---|---|
US (2) | US8349586B1 (en) |
EP (1) | EP1786445B1 (en) |
AT (1) | ATE511848T1 (en) |
WO (1) | WO2006036406A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7195826B2 (en) | 2010-05-06 | 2022-12-26 | ハーバナ リミティド | biological female contraceptive |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3693010A1 (en) | 2012-04-06 | 2020-08-12 | Cornell University | Subunit vaccine delivery platform for robust humoral and cellular immune responses |
US10900043B2 (en) | 2014-09-02 | 2021-01-26 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating bacterial disease |
WO2016036839A1 (en) * | 2014-09-02 | 2016-03-10 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating gonorrhea |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
EP3903766A1 (en) | 2016-04-19 | 2021-11-03 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Use of gram negative species to treat atopic dermatitis |
US10293005B2 (en) | 2016-04-19 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of gram negative species to treat atopic dermatitis |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US10973841B2 (en) | 2018-05-11 | 2021-04-13 | Forte Subsidiary, Inc. | Compositions for the treatment of skin conditions |
CA3131796C (en) | 2019-03-04 | 2023-10-03 | Celloryx AG | Chloride-inducible prokaryotic expression system |
EP3882260A1 (en) * | 2020-03-18 | 2021-09-22 | NUMAFERM GmbH | Fragments of hlya and uses thereof |
WO2021185969A1 (en) | 2020-03-18 | 2021-09-23 | Numaferm Gmbh | Variants of hlya and uses thereof |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2022194403A1 (en) | 2021-03-18 | 2022-09-22 | Numaferm Gmbh | Fusion proteins comprising gg repeat sequences |
EP4339202A1 (en) | 2022-09-16 | 2024-03-20 | NUMAFERM GmbH | Fusion proteins comprising gg repeat sequences ii |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228297A1 (en) * | 2002-03-08 | 2003-12-11 | Osel, Inc. | Lactobacilli expressing biologically active polypeptides and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4952496A (en) * | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US5804179A (en) | 1985-12-31 | 1998-09-08 | Research Corporation Technologies, Inc. | Lactobacillus compositions and methods for treating urinary tract infections |
US5356797A (en) * | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
US6180100B1 (en) | 1994-09-30 | 2001-01-30 | Urex Biotech., Inc. | Lactobacillus compositions and methods for treating urinary tract infections |
IT1270123B (en) | 1994-10-05 | 1997-04-28 | Dompe Spa | PHARMACEUTICAL COMPOSITIONS CONTAINING ENGINEERED MICROORGANISMS AND THEIR USE FOR THERAPY |
WO1996011708A1 (en) * | 1994-10-18 | 1996-04-25 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
US5733540A (en) | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
US5843882A (en) | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
GB9521568D0 (en) | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
FR2747046B1 (en) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | NEW PLASMOVIRUS VACCINES |
FR2760750B1 (en) * | 1997-03-17 | 1999-05-28 | Sanofi Sa | HUMAN NEUROTENSIN TYPE 2 RECEPTOR (HNT-R2) |
US6399584B1 (en) * | 1998-03-18 | 2002-06-04 | Institute Curie | Pharmaceutical composition containing ezrin mutated on tyrosine 353 |
DK0956858T3 (en) | 1998-04-30 | 2002-01-28 | Vesely Renata Maria Cavaliere | Pharmaceutical preparations containing lactobacilli for the treatment of vaginal infections |
BR9915732A (en) * | 1998-11-16 | 2001-09-04 | Genway Biotech Inc | Antibody generation using polynucleotide vaccination in bird species |
CN1355690A (en) | 1999-04-16 | 2002-06-26 | 奥赛尔股份有限公司 | Method for improving half-life of soluble viral-specific ligands on mucosal membranes |
WO2002081655A2 (en) * | 2001-03-28 | 2002-10-17 | Children's Medical Center Corporation | Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo |
JP3722740B2 (en) | 2001-11-05 | 2005-11-30 | 三菱電機株式会社 | Video processing apparatus and video processing method |
US7144712B2 (en) * | 2003-07-30 | 2006-12-05 | Vaccine Research Institute Of San Diego | Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
-
2005
- 2005-08-25 EP EP05814101A patent/EP1786445B1/en active Active
- 2005-08-25 AT AT05814101T patent/ATE511848T1/en not_active IP Right Cessation
- 2005-08-25 WO PCT/US2005/030216 patent/WO2006036406A2/en active Application Filing
-
2007
- 2007-02-26 US US11/710,512 patent/US8349586B1/en active Active
-
2013
- 2013-01-07 US US13/735,638 patent/US20130209407A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228297A1 (en) * | 2002-03-08 | 2003-12-11 | Osel, Inc. | Lactobacilli expressing biologically active polypeptides and uses thereof |
Non-Patent Citations (11)
Title |
---|
BENINATI C ET AL: "Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 18, no. 10, October 2000 (2000-10-01), pages 1060 - 1064, XP002261610, ISSN: 1087-0156 * |
CHANG THERESA L-Y ET AL: "Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 30 SEP 2003, vol. 100, no. 20, 30 September 2003 (2003-09-30), pages 11672 - 11677, XP002371508, ISSN: 0027-8424 * |
ECKERT D M ET AL: "MECHANISMS OF VIRAL MEMBRANE FUSION AND ITS INHIBITION", ANNUAL REVIEW OF BIOCHEMISTRY, PALTO ALTO, CA, US, vol. 70, 2001, pages 777 - 810, XP001152929, ISSN: 0066-4154 * |
FERNÁNDEZ L A ET AL: "Specific secretion of active single-chain Fv antibodies into the supernatants of Escherichia coli cultures by use of the hemolysin system.", APPLIED AND ENVIRONMENTAL MICROBIOLOGY. NOV 2000, vol. 66, no. 11, November 2000 (2000-11-01), pages 5024 - 5029, XP002371602, ISSN: 0099-2240 * |
GIOMARELLI BARBARA ET AL: "The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1.", AIDS (LONDON, ENGLAND) 5 JUL 2002, vol. 16, no. 10, 5 July 2002 (2002-07-05), pages 1351 - 1356, XP002371509, ISSN: 0269-9370 * |
KRUGER C ET AL: "In situ delivery of passive immunity by lactobacilli producing single-chain antibodies", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 20, no. 7, July 2002 (2002-07-01), pages 702 - 706, XP002321895, ISSN: 1087-0156 * |
KRUIS W ET AL: "Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.", GUT. NOV 2004, vol. 53, no. 11, November 2004 (2004-11-01), pages 1617 - 1623, XP002371510, ISSN: 0017-5749 * |
RAO SRINIVAS ET AL: "Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 23 AUG 2005, vol. 102, no. 34, 23 August 2005 (2005-08-23), pages 11993 - 11998, XP002371507, ISSN: 0027-8424 * |
REMBACKEN B ET AL: "Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 354, no. 9179, 21 August 1999 (1999-08-21), pages 635 - 639, XP004831404, ISSN: 0140-6736 * |
TROMM A ET AL: "The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial.", ZEITSCHRIFT FÜR GASTROENTEROLOGIE. MAY 2004, vol. 42, no. 5, May 2004 (2004-05-01), pages 365 - 369, XP009063168, ISSN: 0044-2771 * |
TZSCHASCHEL B D ET AL: "AN ESCHERICHIA COLI HEMOLYSIN TRANSPORT SYSTEM-BASED VECTOR FOR THEEXPORT OF POLYPEPTIDES: EXPORT OF SHIGA-LIKE TOXIN IIEB SUBUNIT BY SALMONELLA TYPHIMURIUM AROA", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 14, June 1996 (1996-06-01), pages 765 - 769, XP002060319, ISSN: 1087-0156 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7195826B2 (en) | 2010-05-06 | 2022-12-26 | ハーバナ リミティド | biological female contraceptive |
Also Published As
Publication number | Publication date |
---|---|
EP1786445B1 (en) | 2011-06-08 |
ATE511848T1 (en) | 2011-06-15 |
EP1786445A2 (en) | 2007-05-23 |
US20130209407A1 (en) | 2013-08-15 |
US8349586B1 (en) | 2013-01-08 |
WO2006036406A2 (en) | 2006-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006036406A3 (en) | Live microbial microbicides | |
MXPA05009352A (en) | Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections. | |
WO2008041966A3 (en) | Broad spectrum antibacterial compounds | |
CA2747703C (en) | Compositions and methods for the treatment or the prevention of infections by e. coli | |
EP2368569A3 (en) | Compositions and methods related to staphylococcal bacterium proteins | |
IL230244A (en) | Crystalline or crystal-like lipopeptide and a method for manufacturing it, pharmaceutical composition comprising the crystalline or crystal-like lipopeptide and use thereof and a method for storing a lipopeptide | |
EP1719410A4 (en) | Method of controlling plant disease damage by using bacillus and controlling agent | |
WO2002060458A3 (en) | Compositions and method of tissue superoxygenation | |
WO2004110341A3 (en) | Antimicrobial and anticancer lipopeptides | |
WO2007085852A3 (en) | Antimicrobial materials | |
TW200716162A (en) | Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria | |
DE60207277D1 (en) | BACTERIAL VACCINE | |
EP3939599A3 (en) | Silicate containing compositions and methods of treatment | |
MXPA05009449A (en) | Pyridinium salts, compounds and methods of use. | |
EP1639971A4 (en) | Skin protecting compositions | |
SE0402807D0 (en) | Novel antimicrobial peptides | |
WO2006123164A3 (en) | Lps-binding and bactericidal cytokines and interferons | |
NO20014788D0 (en) | A composition for lowering the concentration of pathogenic intestinal peptides | |
WO2007092582A3 (en) | Neutralization of bacterial spores | |
RU99117158A (en) | PSEUDOMONAS AERUGINOSA 5142 STRAIN BACTERIA USED TO MAKE A VACCINE AGAINST Pseudomonosis of fur animals | |
ATE308883T1 (en) | HERBICIDES | |
DK1074266T3 (en) | Live attenuated bacteria for use in vaccine | |
RU2003110469A (en) | STRAIN OF BACTERIA BACILLUS SUBTILIS CH-13 | |
WO2006066224A3 (en) | Virulence targeted antibiotics | |
WO2001087931A3 (en) | Bacterial insecticidal proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005814101 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005814101 Country of ref document: EP |